Cargando…

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience important response rates and improved survival, many others do not benefit from ICIs developing hyper-progressive disease or immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costantini, Adrien, Takam Kamga, Paul, Dumenil, Coraline, Chinet, Thierry, Emile, Jean-François, Giroux Leprieur, Etienne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769436/ https://www.ncbi.nlm.nih.gov/pubmed/31470546 http://dx.doi.org/10.3390/cancers11091269

Ejemplares similares

Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
por: Costantini, Adrien, et al.
Publicado: (2020)

Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer
por: Mehlman, Camille, et al.
Publicado: (2021)

Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression
por: Giroux Leprieur, Etienne, et al.
Publicado: (2020)

Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients
por: Dacosta-Noble, Philippine, et al.
Publicado: (2019)

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
por: Dumenil, Coraline, et al.
Publicado: (2018)

Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration
por: Wang, Lei, et al.
Publicado: (2017)

High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2021)

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors
por: Takam Kamga, Paul, et al.
Publicado: (2022)

Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab
por: Ouaknine Krief, Julia, et al.
Publicado: (2019)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
por: Dal Collo, Giada, et al.
Publicado: (2023)

Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report
por: Magdelaine, Pierre, et al.
Publicado: (2022)

Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance
por: Giroux-Leprieur, Etienne, et al.
Publicado: (2018)

Editorial: Influence of potential diagnostic biomarkers in lung cancer
por: Takam Kamga, Paul
Publicado: (2023)

Old Sonic Hedgehog, new tricks: a new paradigm in thoracic malignancies
por: Giroux Leprieur, Etienne, et al.
Publicado: (2018)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Leprieur, Etienne Giroux, et al.
Publicado: (2016)

Successful pulmonary arterial embolization followed by curative surgery for a lepidic predominant lung adenocarcinoma with severe hypoxemia
por: Sebane, Louise, et al.
Publicado: (2018)

Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells
por: Bazzoni, Riccardo, et al.
Publicado: (2020)

Impact of Waiting Response Evaluation to First-Line Systemic Therapy before Considering Local Ablative Therapy in Metastatic Non-Small-Cell Lung Cancer
por: Belaidi, Lahcene, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

New biomarkers for checkpoint inhibitor therapy
por: Burdett, Nikki, et al.
Publicado: (2020)

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
por: Costantini, Adrien, et al.
Publicado: (2018)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies
por: Tanasi, Ilaria, et al.
Publicado: (2020)

Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study
por: Ezzedine, Rémy, et al.
Publicado: (2023)

Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma
por: Masson, Claire, et al.
Publicado: (2023)

Response to a letter to the editor: a better understanding of Immune Checkpoint Inhibitor-induced cholangitis for better management
por: Coukos, Alexander, et al.
Publicado: (2023)

Biomarkers to predict prognosis and response to checkpoint inhibitors
por: Yuasa, Takeshi, et al.
Publicado: (2017)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
por: Haist, Maximilian, et al.
Publicado: (2023)

Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors
por: Rozensztajn, Nathalie, et al.
Publicado: (2014)

Biomarker Trends, Incidence, and Outcomes of Immune Checkpoint Inhibitor–Induced Myocarditis
por: Vasbinder, Alexi, et al.
Publicado: (2022)

Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia
por: Takam Kamga, Paul, et al.
Publicado: (2019)

Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis
por: Yogasundaram, Haran, et al.
Publicado: (2020)

Acute exacerbation of COPD during pulmonary rehabilitation: outcomes and risk prediction
por: Herer, Bertrand, et al.
Publicado: (2018)

Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients
por: Hirshoren, Nir, et al.
Publicado: (2020)

Preclinical characterization of therapeutic antibodies targeted at the carboxy-terminus of Sonic hedgehog
por: Tolani, Bhairavi, et al.
Publicado: (2018)

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
por: Costa Svedman, Fernanda, et al.
Publicado: (2022)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6acbt1md43m0kqhsi9fj28126d